![Quiver Logo](/static/img/logo-icon.png)
![CRGX logo](https://quiver-logos.s3.us-east-2.amazonaws.com/crgx.png)
CARGO Therapeutics, Inc. Common Stock
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CRGX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of CRGX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CRGX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to CRGX
Recent picks made for CRGX stock on CNBC
ETFs with the largest estimated holdings in CRGX
Flights by private jets registered to CRGX
![Quiver Logo](/static/img/logo-icon.png)